Stockscreener 앱 받기
6.88
3.93%
0.26
시간 외 거래:
6.88
전일 마감가:
$6.62
열려 있는:
$6.76
하루 거래량:
790.77K
Relative Volume:
0.63
시가총액:
$677.33M
수익:
$14.79M
순이익/손실:
$-174.33M
주가수익비율:
-3.4027
EPS:
-2.0219
순현금흐름:
$-157.44M
1주 성능:
+13.16%
1개월 성능:
-13.13%
6개월 성능:
+28.36%
1년 성능:
+144.84%
1일 변동 폭
$6.70
$6.93
1주일 범위
$6.098
$6.93
52주 변동 폭
$2.83
$8.8661
솔리드 바이오 Stock (SLDB) Company Profile
명칭
Solid Biosciences Inc
전화
617-337-4680
주소
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
6.88 | 651.74M | 14.79M | -174.33M | -157.44M | -2.0219 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
솔리드 바이오 Stock (SLDB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-20 | 개시 | Guggenheim | Buy |
| 2025-12-04 | 개시 | Needham | Buy |
| 2025-06-26 | 개시 | Citigroup | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-13 | 개시 | Wedbush | Outperform |
| 2024-12-10 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-15 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-06-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-03-28 | 개시 | William Blair | Outperform |
| 2024-03-15 | 개시 | Citigroup | Buy |
| 2024-03-14 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | 개시 | H.C. Wainwright | Buy |
| 2021-07-12 | 개시 | Piper Sandler | Neutral |
| 2021-05-27 | 개시 | Jefferies | Buy |
| 2021-03-16 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | 개시 | Barclays | Overweight |
| 2021-01-08 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-10-11 | 개시 | Evercore ISI | Outperform |
| 2019-08-29 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2019-08-19 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-02-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2019-02-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | 개시 | Citigroup | Sell |
| 2018-09-06 | 개시 | Credit Suisse | Neutral |
모두보기
솔리드 바이오 주식(SLDB)의 최신 뉴스
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
J.P. Morgan Maintains Solid Biosciences(SLDB.US) With Buy Rating, Cuts Target Price to $11 - Moomoo
SLDB Stock Price, Quote & Chart | SOLID BIOSCIENCES INC (NASDAQ:SLDB) - ChartMill
Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months? - Insider Monkey
10 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Value Gem With Solid Fundamentals - ChartMill
SLDB Reiterated by Wedbush -- Price Target Maintained at $16.00 - GuruFocus
Solid Biosciences Price Target Maintained With a $16.00/Share by Wedbush - Moomoo
SLDB: Citigroup Lowers Price Target but Maintains Buy Rating | S - GuruFocus
H.C. Wainwright Remains a Buy on Solid Biosciences (SLDB) - The Globe and Mail
Citigroup Maintains Solid Biosciences (SLDB) Buy Recommendation - MSN
Solid Biosciences stock (US8317541063): Piper Sandler raises price target to $18 - AD HOC NEWS
Solid Biosciences Inc. to host webinar on SGT-003 gene therapy for Duchenne - Traders Union
Number of shareholders of Solid Biosciences Inc. – NASDAQ:SLDB - TradingView
Wedbush Adjusts Price Target on Solid Biosciences to $16 From $17, Maintains Outperform Rating - Moomoo
SLDB Maintained by Piper Sandler -- Price Target Raised to $18 - GuruFocus
Wedbush Maintains Solid Biosciences(SLDB.US) With Buy Rating, Cuts Target Price to $16 - Moomoo
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Solid Biosciences (SLDB) boosts cash to $380.7M while Q1 net loss widens - Stock Titan
Solid Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MSN Money - MSN
TradingKey - TradingKey
Solid Biosciences Inc expected to post a loss of 43 cents a shareEarnings Preview - TradingView
SLDB SEC FilingsSolid Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan
William Blair Maintains Solid Biosciences(SLDB.US) With Buy Rating - Moomoo
Solid Biosciences begins phase 3 trial for Duchenne therapy By Investing.com - Investing.com South Africa
Solid Biosciences begins phase 3 trial for Duchenne therapy - Investing.com
A Duchenne treatment reaches Phase 3 after 46 patients dosed - Stock Titan
Solid Biosciences Doses First Participant in Phase 3 IMPACT - GlobeNewswire
Solid Biosciences Chief Medical Officer presents targeted therapy delivery approach at Boston biotech conference - Traders Union
SLDB: JP Morgan Raises Price Target to $12 with Overweight Ratin - GuruFocus
Invus and affiliates hold 9.99% of Solid Biosciences (NASDAQ: SLDB) via warrants and shares - Stock Titan
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
One new Solid Biosciences employee gets 8,070 stock units - Stock Titan
SLDB: HC Wainwright & Co. Reiterates Buy Rating with $20 Target - GuruFocus
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy - marketscreener.com
Solid Biosciences to Showcase a Large Presence at the 29th - GlobeNewswire
Solid Bio wins new buy at Guggenheim on lead asset - MSN
Solid Biosciences receives EU orphan drug status for SGT-003 - Investing.com UK
Solid Biosciences (SLDB) Receives Orphan Drug Designation for SG - GuruFocus
Solid Biosciences receives EU orphan drug status for SGT-003 By Investing.com - Investing.com South Africa
솔리드 바이오 (SLDB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):